Esophageal Cancer Clinical Trial
Official title:
Extraesophageal Saline Injection Combined With EUS to Differentiate Between T3 and T4 Stage Esophageal Squamous Cell Carcinoma — A PhaseⅠTrial
By using a novel technique of extraesophageal saline injection (ESI),the esophagus is to be separate from the adjacent organs.The space between esophagus and adjacent organs can be detected by endoscopic ultrasonography enhanced with ESI.Therefore, ESI plus with EUS is to be differentiate between T3 and T4 stage esophageal squamous cell carcinoma (ESCC). The objective of this Phase Ⅰstudy is to confirm the safety and efficacy of ESI.
Esophageal cancer (EC) is one of the most common malignant tumors in the world, and China
has the highest incidence of esophageal squamous cell carcinoma (ESCC).According to the TNM
staging system of the Union for International Cancer Control (UICC) (7th Edition, 2012), EC
invades the esophageal adventitia at the T3 stage; invades the pleura, pericardium and
diaphragm at the T4a stage; and involves adjacent vital organs (mainly the thoracic aorta,
aortic arch, trachea, tracheal bifurcation, and spine) at the T4b stage.It is considered
that T3- and T4a-stage tumors can be surgically resected, while tumors at the T4b stage are
not suitable for surgical resection.Therefore, it is important for physicians and patients
to know whether the tumor has metastasized to adjacent organs before considering resection.
The preoperative stage is unclear in many cases of progressive disease and the involvement
of vital organs is only discovered by exploratory thoracotomy, because of which the
resection may need to be terminated prematurely, leading to unnecessary injuries.Therefore,
accurate preoperative staging of EC, especially during the later stages, is important for
deciding the appropriate therapeutic option and evaluation of the prognosis.
The imaging methods used for preoperative staging of EC include endoscopic ultrasonography
(EUS). However, EUS has poor accuracy in advanced ESCC, especially in T3 and T4 stage ESCC.
Therefore, it is necessary to improve the preoperative accuracy of EUS for advanced EC.
Since extraesophageal space contains loose connective tissue and saline can permeate into
extraesophageal space and separate esophagus from adjacent organ; furthermore, saline serves
as an EUS contrast agent (negative) and is detected by EUS.Therefore, we envisaged that if
saline is directly injected into extraesophageal space, the separation between the
esophageal adventitia and its adjacent organs (especially the thoracic aorta, arcus aortae,
and tracheal bifurcation) can be observed by EUS. In our recent experiment in canine model,
guided by EUS,extraesophageal saline injection was successfully conducted and saline
separated esophageal adventitia from adjacent organs including thoracic aorta, arcus aortae,
trachea and bronchial bifurcation without any complication.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |